Feedback PLC NHS publication on potential application of TexRAD
06 Oktober 2015 - 10:45AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
06 October 2015
Feedback plc
("Feedback" or the "Company")
NHS England "Alert" published on the potential application of
TexRAD for assessing patients with lung cancer
Feedback plc (AIM: FDBK), the medical imaging software company
is pleased to announce that the research arm of NHS England has
published an "Alert" on the potential application of Feedback's
TexRAD CT texture analysis software for assessing patients with
lung cancer. The National Institute for Health Research through its
Horizon Scanning Research and Intelligence Centre (NIHR HSRIC)
based at the University of Birmingham, England has also posted the
Alert on its publicly accessible website.
(www.hsric.nihr.ac.uk)
NIHR HSRIC is an academic unit which independently investigates
and provides advanced notice of new and emerging medical devices
and diagnostics that have the potential to positively impact upon
the NHS within the next two years. Before writing the Alert, NIHR
HSRIC looked at TexRAD CT texture analysis technology and its
potential use for assessing patients with different cancers but
particularly for those with lung cancer. The Alert will be
distributed within the NHS and to national healthcare organisations
and policy makers such as the National Institute for Health and
Care Excellence (NICE) and the UK National Screening Committee.
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer
of the Company's subsidiaries TexRAD Ltd & Cambridge Computed
Imaging Ltd commented:
"The Alert from the NHS's research arm is a significant step
towards potentially obtaining NICE approval for TexRAD to be used
as a clinical tool for assessing patients with lung cancer. This
adds to the recently announced clinical adoption study focused on
lung cancer being undertaken by Professor Ken Miles at the Princess
Alexandra Hospital, Brisbane, Australia. "
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell / Trevor Brown
/ Tom Charlton
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
is readily visible to the naked eye. Research to date has shown
that TexRAD could potentially assist the clinician (as an
'Imaging-Biomarker') in confident decision-making: it has the
potential to assess the prognosis, disease-severity (e.g. risk of
metastases) and response evaluation of patients with cancer.
Currently TexRAD research has shown great potential in many
different oncological sites, including, colorectal, breast, lung,
prostate, oesophageal, head & neck, lymphoma, liver and renal
cancers and could potentially be employed as a heterogeneity
assessing tool in the era of 'Precision and Personalized Medicine'.
TexRAD is manufactured under licence by company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKADNFBDKFKK
(END) Dow Jones Newswires
October 06, 2015 04:45 ET (08:45 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024